Specifically, this novel peptide–drug conjugate (1) is cytotoxic against pancreatic lines, including one metastatic line, (2) reduces the viability of patient-derived tumor organoids, and (3) shows a significantly lower cytotoxicity for non-tumorous transformed cells, as opposed to Gem exposure. The gene discussed is GEM; the disease is neoplasm.